Graves disease in children: Thyroid-stimulating hormone receptor antibodies as remission markers

Roberto Gastaldi, Elena Poggi, Alessandro Mussa, Giovanna Weber, Maria Cristina Vigone, Mariacarolina Salerno, Maurizio Delvecchio, Elena Peroni, Angela Pistorio, Andrea Corrias

Research output: Contribution to journalArticlepeer-review


Objective To evaluate clinical and biochemical features of 115 children (98 female, mean age 11.3 ± 3.5 years) with Graves disease to identify possible determinants of remission. Study design We defined as positive outcome the improvement of clinical features and restoration of euthyroidism or induction of hypothyroidism after antithyroid drug (ATD) therapy and as negative outcome hyperthyroidism persistent over 2 years of ATD therapy or relapsed after ATD withdrawal. Results Thirty-eight children (33%) had remission after 2 years of ATD therapy. The absence of goiter at diagnosis was correlated with a better outcome. Median thyroid-stimulating hormone receptor antibody (TRAb) values at diagnosis were significantly lower in patients with a positive outcome (P =.031). We found a significant relationship between the time required for TRAb normalization and the patient outcome; TRAb normalization within 1 year from time of Graves disease diagnosis was significantly more common among patients with a positive outcome (P

Original languageEnglish
JournalJournal of Pediatrics
Issue number5
Publication statusPublished - 2014


  • Antithyroid drug
  • ATD
  • BMI
  • Body mass index
  • Free thyroxine
  • Free triiodothyronine
  • fT3
  • fT4
  • Receiver operating curve
  • ROC
  • Thyroid-stimulating hormone
  • Thyroid-stimulating hormone receptor antibody
  • TRAb
  • TSH

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Graves disease in children: Thyroid-stimulating hormone receptor antibodies as remission markers'. Together they form a unique fingerprint.

Cite this